WithdrawnPhase 2

A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM

Stopped: Business decision to move away from this indication with this intervention, and low enrollment.

United Arab Emirates0Started 2026-01-06

Plain-language summary

The purpose of this study is to evaluate the efficacy and safety of ofirnoflast in combination with semaglutide in comparison to semaglutide alone in obese participants with T2DM.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Postmenopausal (\>45 years of age with amenorrhea for at least 12 months, without using exogenous hormonal contraception and with FSH ≥ 40 IU/L).
✓. Surgically sterile (hysterectomy, bilateral salpingectomy; oophorectomy) for at least 6 months.
✓. Using a double contraception including a barrier method (condom, diaphragm, or occlusive cap) and a highly effective method of birth control, which includes the following:

What they're measuring

Assess glycemic control using HbA1c (%)

Timeframe: From first dose through End of Study (up to 12 weeks per participant)

Assess weight loss using body weight measurements

Timeframe: From first dose through End of Study (up to 12 weeks per participant)

Trial details

NCT IDNCT07172867

SponsorHalia Therapeutics, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-01-23

View on ClinicalTrials.gov More Diabetes Mellitus, Type 2 trials